Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients

被引：0
作者：
Ayush Jain
Bhupinder Singh Kalra
Siddharth Srivastava
Shalini Chawla
机构：
[1] Maulana Azad Medical College,Department of Pharmacology
[2] Govind Ballabh Pant Institute of Postgraduate Medical Education and Research,Department of Gastroenterology
来源：
Indian Journal of Gastroenterology | 2019年 / 38卷
关键词：
Antiviral therapy; Cholesterol; Daclatasvir; Hepatitis C; Quality of life; Sofosbuvir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：39 / 43
页数：4
相关论文
共 56 条
  • [1] Kim CW(2013)Hepatitis C virus: virology and life cycle Clin Mol Hepatol 19 17-25
  • [2] Chang KM(2016)Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection Expert Rev Gastroenterol Hepatol 10 13-20
  • [3] Sundaram V(2001)Prevalence of hepatitis C genotypes in Indian patients and their clinical significance J Assoc Physicians India 49 983-985
  • [4] Amarapurkar D(2010)Management of acute hepatitis C Clin Liver Dis 14 169-176
  • [5] Dhorda M(2015)Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses Antivir Res 124 110-121
  • [6] Kirpalani A(2015)Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes World J Gastroenterol 21 8293-8303
  • [7] Amarapurkar A(2014)Hepatitis C virus infection and type 1 and type 2 diabetes mellitus World J Diabetes 5 586-600
  • [8] Kankonkar S(2015)Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir Clin Pharmacokinet 54 677-690
  • [9] Maheshwari A(2016)Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection Ann Pharmacother 50 39-46
  • [10] Thuluvath PJ(2014)The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients Clin Mol Hepatol 20 38-46
123456